GR1005424B - Μεθοδος για τον ποσοτικο προσδιορισμο της εκφρασης της ck19 - Google Patents

Μεθοδος για τον ποσοτικο προσδιορισμο της εκφρασης της ck19

Info

Publication number
GR1005424B
GR1005424B GR20050100430A GR20050100430A GR1005424B GR 1005424 B GR1005424 B GR 1005424B GR 20050100430 A GR20050100430 A GR 20050100430A GR 20050100430 A GR20050100430 A GR 20050100430A GR 1005424 B GR1005424 B GR 1005424B
Authority
GR
Greece
Prior art keywords
quantitative determination
expression
positive cells
biological samples
relates
Prior art date
Application number
GR20050100430A
Other languages
English (en)
Inventor
Βασιλης Γεωργουλιας
Δημητριος Μαυρουδης
Ευρυκλεια Λιανιδου
Αλικη Σταθοπουλου
Original Assignee
Medexis Αεβε
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medexis Αεβε filed Critical Medexis Αεβε
Priority to GR20050100430A priority Critical patent/GR1005424B/el
Priority to JP2008526444A priority patent/JP2009504168A/ja
Priority to PCT/EP2006/008097 priority patent/WO2007020081A1/en
Priority to EP06776902.6A priority patent/EP1915461B1/en
Priority to AU2006281569A priority patent/AU2006281569A1/en
Priority to US11/990,575 priority patent/US20100015604A1/en
Priority to KR1020087006461A priority patent/KR20080036646A/ko
Priority to CN200680037658.3A priority patent/CN101365800B/zh
Priority to CA002617693A priority patent/CA2617693A1/en
Publication of GR1005424B publication Critical patent/GR1005424B/el
Priority to US14/031,051 priority patent/US9593374B2/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μία μέθοδο για τον ποσοτικό προσδιορισμό κυττάρων θετικών σε mRNA της CK-19 σε βιολογικά δείγματα. Ειδικότερα, η εφεύρεση αφορά μία μέθοδο για ποσοτικό προσδιορισμό κυττάρωνθετικών σε mRNA της CK-19 σε βιολογικά δείγματα ασθενών που πάσχουν από καρκίνο πριν από την εκκίνηση επικουρικής θεραπείας προκειμένου να παρασχεθούν πληροφορίες σχετικά με την αποτελεσματικότητα της επικουρικής θεραπείας.
GR20050100430A 2005-08-17 2005-08-17 Μεθοδος για τον ποσοτικο προσδιορισμο της εκφρασης της ck19 GR1005424B (el)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GR20050100430A GR1005424B (el) 2005-08-17 2005-08-17 Μεθοδος για τον ποσοτικο προσδιορισμο της εκφρασης της ck19
JP2008526444A JP2009504168A (ja) 2005-08-17 2006-08-16 Ｃｋ１９発現を確認する組成物及び方法
PCT/EP2006/008097 WO2007020081A1 (en) 2005-08-17 2006-08-16 Composition and method for determination of ck19 expression
EP06776902.6A EP1915461B1 (en) 2005-08-17 2006-08-16 Composition and method for determination of ck19 expression
AU2006281569A AU2006281569A1 (en) 2005-08-17 2006-08-16 Composition and method for determination of CK19 expression
US11/990,575 US20100015604A1 (en) 2005-08-17 2006-08-16 Composition and method for determination of ck19 expression
KR1020087006461A KR20080036646A (ko) 2005-08-17 2006-08-16 Ｃｋ１９ 발현 측정을 위한 조성물 및 방법
CN200680037658.3A CN101365800B (zh) 2005-08-17 2006-08-16 用于确定ck19表达的组合物和方法
CA002617693A CA2617693A1 (en) 2005-08-17 2006-08-16 Composition and method for determination of ck19 expression
US14/031,051 US9593374B2 (en) 2005-08-17 2013-09-19 Composition and method for determination of CK19 expression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20050100430A GR1005424B (el) 2005-08-17 2005-08-17 Μεθοδος για τον ποσοτικο προσδιορισμο της εκφρασης της ck19

Publications (1)

Publication Number Publication Date
GR1005424B true GR1005424B (el) 2007-02-01

Family

ID=38121845

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20050100430A GR1005424B (el) 2005-08-17 2005-08-17 Μεθοδος για τον ποσοτικο προσδιορισμο της εκφρασης της ck19

Country Status (2)

Country Link
CN (1) CN101365800B (el)
GR (1) GR1005424B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102565404B (zh) * 2010-12-24 2014-04-16 牛刚 一种检测血液中游离大肠癌细胞标志物的试剂盒
CN102109525B (zh) * 2011-01-26 2013-10-16 牛刚 一种检测血液中游离乳腺癌细胞标志物的试剂盒
CN103122387B (zh) * 2013-02-05 2015-02-04 苏州华益美生物科技有限公司 循环肿瘤细胞(CTCs)荧光PCR快速超敏检测试剂盒及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097878A1 (en) * 2002-05-21 2003-11-27 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
ATE548447T1 (de) * 2004-01-14 2012-03-15 Novahep Ab Menschlicher hepatische vorläuferzellen und verfahren zur verwendung davon

Also Published As

Publication number Publication date
CN101365800B (zh) 2014-07-02
CN101365800A (zh) 2009-02-11

Similar Documents

Publication Publication Date Title
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
WO2007081680A3 (en) Microrna expression abnormalities in pancreatic endocrine and acinar tumors
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
MX394667B (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4- ciano-3-trifluorometll-fen|l)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ilideno]-tiourea.
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
ZA200803517B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
IL190852A0 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
ZA200804509B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
ZA200803516B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2009074968A3 (en) Method for predicting the efficacy of cancer therapy
WO2008106175A3 (en) Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
IL182813A0 (en) Methods and systems for prognosis and treatment of solid tumors
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
MY147634A (en) New crystalline forms
WO2008089135A3 (en) Identification of biomarkers predictive of dasatinib effects in cancer cells
WO2009023846A3 (en) Methods for heat shock protein dependent cancer treatment

Legal Events

Date Code Title Description
PG Patent granted
ML Lapse due to non-payment of fees

Effective date: 20120302